247 related articles for article (PubMed ID: 26394624)
1. Epithelial-mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma.
Breyer J; Gierth M; Shalekenov S; Aziz A; Schäfer J; Burger M; Denzinger S; Hofstädter F; Giedl C; Otto W
World J Urol; 2016 May; 34(5):709-16. PubMed ID: 26394624
[TBL] [Abstract][Full Text] [Related]
2. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer.
Zhao J; Dong D; Sun L; Zhang G; Sun L
Int Braz J Urol; 2014; 40(2):179-89. PubMed ID: 24856504
[TBL] [Abstract][Full Text] [Related]
5. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
[TBL] [Abstract][Full Text] [Related]
6. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.
Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP
J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899
[TBL] [Abstract][Full Text] [Related]
7. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
March-Villalba JA; Ramos-Soler D; Soriano-Sarrió P; Hervás-Marín D; Martínez-García L; Martínez-Jabaloyas JM
Urol Oncol; 2019 Feb; 37(2):158-165. PubMed ID: 30446453
[TBL] [Abstract][Full Text] [Related]
9. Krüppel-like factor 4 is a novel prognostic predictor for urothelial carcinoma of bladder and it regulates TWIST1-mediated epithelial-mesenchymal transition.
Tseng WC; Chuang CW; Yang MH; Pan CC; Tarng DC
Urol Oncol; 2016 Nov; 34(11):485.e15-485.e24. PubMed ID: 27519276
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-To-Mesenchymal Transition and Its Correlation With Clinicopathologic Features in Patients With Urothelial Carcinoma of the Bladder.
Singh R; Ansari JA; Maurya N; Mandhani A; Agrawal V; Garg M
Clin Genitourin Cancer; 2017 Apr; 15(2):e187-e197. PubMed ID: 27601277
[TBL] [Abstract][Full Text] [Related]
12. T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-IIα, survivin, and E-cadherin.
Raspollini MR; Luque RJ; Menendez CL; Bollito E; Brunelli M; Martignoni G; Montironi R; Cheng L; Blanca A; Baroni G; Minervini A; Lopez-Beltran A
Hum Pathol; 2016 Nov; 57():78-84. PubMed ID: 27473264
[TBL] [Abstract][Full Text] [Related]
13. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
14. Expression of E-cadherin, Ki-67, and p53 in urinary bladder cancer in relation to progression, survival, and recurrence.
Ziaran S; Harsanyi S; Bevizova K; Varchulova Novakova Z; Trebaticky B; Bujdak P; Galbavy S; Danisovic L
Eur J Histochem; 2020 Mar; 64(2):. PubMed ID: 32214283
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
[TBL] [Abstract][Full Text] [Related]
16. Expression profile of epithelial-mesenchymal transition markers in non-muscle-invasive urothelial carcinoma of the bladder: correlation with intravesical recurrence following transurethral resection.
Liu B; Miyake H; Nishikawa M; Fujisawa M
Urol Oncol; 2015 Mar; 33(3):110.e11-8. PubMed ID: 25262382
[TBL] [Abstract][Full Text] [Related]
17. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma.
Rao J; Seligson D; Visapaa H; Horvath S; Eeva M; Michel K; Pantuck A; Belldegrun A; Palotie A
Cancer; 2002 Sep; 95(6):1247-57. PubMed ID: 12216092
[TBL] [Abstract][Full Text] [Related]
18. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
19. Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study.
Santi R; Cai T; Nobili S; Galli IC; Amorosi A; Comperat E; Nesi G
Virchows Arch; 2018 Apr; 472(4):605-613. PubMed ID: 29525824
[TBL] [Abstract][Full Text] [Related]
20. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies.
Bryan RT; Atherfold PA; Yeo Y; Jones LJ; Harrison RF; Wallace DM; Jankowski JA
J Pathol; 2008 Jun; 215(2):184-94. PubMed ID: 18393367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
